Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which biologic works best first for ulcerative colitis? major trial aims to find out

NCT ID NCT07576452

Disease control Sponsor: University Hospital, Clermont-Ferrand Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 18, 2026 · Updated 1 time

Summary

This study compares four different sequences of biologic drugs (infliximab, filgotinib, ustekinumab, and vedolizumab) in 240 adults with moderate to severe ulcerative colitis. The goal is to see which order of treatments works best to achieve and maintain remission without steroids. Participants will be followed for two years with regular check-ups and endoscopies.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
infliximab, filgotinib, ustekinumab, vedolizumab
What this could lead to
If successful, this study could identify the best order of biologic treatments for ulcerative colitis, improving remission rates and quality of life.
What could go wrong
This is a Phase 4 trial comparing existing drugs, so no new treatment is being discovered. Results may not apply to all patients, and individual responses can vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 240 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Dec 2026

An estimate. Start dates often move.

Expected to finish

Dec 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female patients (using effective contraception and a negative pregnancy test for women of childbearing age) diagnosed with UC for at least 3 months * Age ≥ 18 years and ≤ 65 years * Moderate to severe UC according to modified Mayo score (from 5 to 9) * With endoscopic Mayo score ≥ 2 * With an inadequate response, failure, loss of response, or intolerance to 5-ASA, steroids, or immunosuppressants. * Patient capable of giving consent * Patient covered by the French healthcare system * Women of childbearing age using active contraception (contraceptive implant, oral contraception, female condom or abstinence)) for at least the duration of the study Exclusion Criteria: * Usual contra-indication to infliximab, filgotinib, vedolizumab or ustekinumab * Steroids \> 20 mg/day within two weeks before inclusion * Low proctitis (disease limited to the rectum with an extent \< 5 cm) * Prior history of thromboembolism events * Prior history of major cardiovascular problems (such as heart attack or stroke) * Long-standing smokers (\> 40 pack years) * Crohn's disease * Stoma or colectomy * Prior exposure to anti-TNF agents, anti-integrins, anti-interleukines 12 and 23 or JAK inhibitor * Prior exposure to other biologics or experimental drug * No health insurance * Pregnant or lactating women : a pregnancy test will be performed for women of childbearing age * Patients already included in biomedical research other than an observational study (e.g: registry, cohort) * Concomitant Clostridioides difficile infection * HIV infection * Patient who does not master the French language * Patient under guardianship, curatorship or safeguard of justice * Minors

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ulcerative colitis (UC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ulcerative colitis (UC)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHD de Vendée

    La Roche-sur-Yon, France

  • CHU de Clermont-Ferrand

    Clermont-Ferrand, France

  • CHU de Montpellier, Service de Neurologie

    Montpellier, 34000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.